Work

Weed-Derived Secondary Metabolites in Polycystic Ovary Syndrome: Target Engagement, Exposure Plausibility and a Safety-Gated Framework for Candidate Prioritization

Year: 2026
Type: article
Study design: Systematic Review
Abstract: Background/Objectives: Existing PCOS reviews largely catalogue natural products and reported molecular pathways. This structured critical review asks a different translational question: which constituents from weed, ruderal and invasive taxa remain credible candidates when target engagement, pharmacological direction, realistic exposure and safety are considered together. Methods: PubMed/MEDLINE, Web of Science Core Collection and CAB Abstracts were searched from inception to 2 September 2026, with CABI resources used to verify weed status. Eligible pharmacological, pharmacokinetic and toxicological evidence was critically appraised using a T1–T4 mechanistic evidence hierarchy and evaluated for exposure plausibility, methodological quality and citation integrity. Results: No positive mechanistic claim reached T3 or T4. Urtica dioica L. lignans demonstrably displace dihydrotestosterone from SHBG in vitro, but the predicted consequence for free androgen exposure in vivo remains untested; flavonoid aromatase effects are assay- and context-dependent; and several widely cited systemic mechanisms are not supported by current exposure data. Silybin exposure supports a narrower liver-directed hypothesis, whereas non-absorbed inulin-type fructans provide a luminal gut-axis case in which systemic exposure is not required. Mentha spicata L. provides a reproducible human endocrine signal but no defined active constituent or molecular target. Conclusions: The principal barrier to clinical translation is not a shortage of activity signals but the absence of demonstrated in vivo target engagement, target-site pharmacokinetics and reproductive-safety qualification. No candidate currently clears all five gates. Silybum marianum flavonolignans and Cichorium intybus inulin-type fructans are therefore only provisionally prioritized for node-specific nonclinical development, while M. spicata is a mechanism-resolution research signal rather than a pharmacological lead. The framework prioritizes the experiments needed to establish development readiness; it does not infer PCOS-specific efficacy from the existing evidence.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7234607627
FWCI:
Cites: 84
Cited by:
Related to: 10